Company Quick10K Filing
Bioxcel Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 16 $172
10-Q 2019-11-14 Quarter: 2019-09-30
10-Q 2019-08-06 Quarter: 2019-06-30
10-Q 2019-05-07 Quarter: 2019-03-31
10-K 2019-03-12 Annual: 2018-12-31
10-Q 2018-11-09 Quarter: 2018-09-30
10-Q 2018-08-08 Quarter: 2018-06-30
10-Q 2018-05-14 Quarter: 2018-03-31
S-1 2018-02-12 Public Filing
8-K 2020-02-19 Earnings, Other Events
8-K 2020-02-18 Enter Agreement, Exhibits
8-K 2020-01-13 Regulation FD
8-K 2019-11-14 Earnings, Exhibits
8-K 2019-09-26 Other Events, Exhibits
8-K 2019-09-22 Leave Agreement
8-K 2019-08-06 Earnings, Exhibits
8-K 2019-07-22 Regulation FD, Other Events, Exhibits
8-K 2019-05-23 Shareholder Vote
8-K 2019-05-22 Regulation FD
8-K 2019-05-20 Regulation FD, Other Events, Exhibits
8-K 2019-05-20 Enter Agreement, Exhibits
8-K 2019-05-07 Earnings, Exhibits
8-K 2019-04-01 Other Events, Exhibits
8-K 2019-03-25 Other Events, Exhibits
8-K 2019-03-11 Other Events, Exhibits
8-K 2019-03-07 Officers, Other Events, Exhibits
8-K 2019-03-07 Earnings, Exhibits
8-K 2019-03-04 Other Events, Exhibits
8-K 2019-02-11 Regulation FD, Exhibits
8-K 2019-02-04 Other Events, Exhibits
8-K 2019-01-03 Regulation FD, Other Events, Exhibits
8-K 2018-12-27 Other Events, Exhibits
8-K 2018-12-19 Other Events, Exhibits
8-K 2018-12-12 Other Events, Exhibits
8-K 2018-12-12 Regulation FD, Exhibits
8-K 2018-11-14 Other Events, Exhibits
8-K 2018-11-09 Earnings, Exhibits
8-K 2018-11-05 Other Events, Exhibits
8-K 2018-10-30 Other Events, Exhibits
8-K 2018-09-21 Enter Agreement, Other Events, Exhibits
8-K 2018-08-20 Enter Agreement, Exhibits
8-K 2018-08-08 Earnings, Exhibits
8-K 2018-07-24 Other Events, Exhibits
8-K 2018-06-27 Other Events, Exhibits
8-K 2018-06-07 Regulation FD, Exhibits
8-K 2018-06-04 Other Events, Exhibits
8-K 2018-06-01 Officers, Exhibits
8-K 2018-05-21 Regulation FD, Exhibits
8-K 2018-05-17 Other Events, Exhibits
8-K 2018-05-14 Earnings, Exhibits
8-K 2018-04-26 Other Events, Exhibits
8-K 2018-03-07 Officers, Amend Bylaw, Other Events, Exhibits

Bioxcel Therapeutics Financials

BTAI Metrics, Comps, Filings

Annual | Quarterly

Business

We are a clinical stage biopharmaceutical company utilizing novel artificial intelligence-based approaches to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need. Our two most advanced clinical development programs are BXCL501, a sublingual thin film formulation of the α2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno‑oncology agent for treatment of a rare form of prostate cancer and pancreatic cancer.

We intend to develop first‑in‑class, high value therapeutics by leveraging EvolverAI, a research and development engine created and owned by our parent, BioXcel Corporation, or BioXcel. We believe the combination of our therapeutic area expertise and our ability to generate product candidates through our exclusive collaborative relationship with BioXcel in the areas of neuroscience and immuno‑oncology gives us a significant competitive advantage. EvolverAI was developed over the last decade and integrates millions of fragmented data points using artificial intelligence, or AI and proprietary machine learning algorithms. After evaluating multiple product candidates using EvolverAI, we selected our lead programs because our analysis indicated these drugs may have utility in new therapeutic indices where there is substantial unmet medical needs and limited competition. By focusing on clinical candidates with relevant human data, we believe our approach will help us design more efficient clinical trials, thereby accelerating our product candidates’ time to market. We retain global development and commercialization rights to these two programs.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Ocular Therapeutix (OCUL) 188,314 22% -4.3 -44% 89,742 81,484 2,144 462 -39,738 -33,359 144,683
Seres Therapeutics (MCRB) 187,368 0% -1.2 -54% 146,093 164,061 39,103 0 -78,328 -70,434 85,024
Strongbridge Biopharma (SBBP) 187,356 0% 2.0 27% 135,156 43,867 20,283 0 36,817 50,910 101,189
MEI Pharma (MEIP) 186,804 13% -6.7 -20% 82,663 34,733 4,914 651 -16,820 -16,739 112,315
Aratana Therapeutics (PETX) 183,720 71% -15.6 -12% 104,712 8,494 38,729 27,360 -12,961 -9,421 146,808
Chimerix (CMRX) 181,357 0% -2.4 -41% 163,441 14,323 9,027 0 -66,378 -66,378 159,713
Cormedix (CRMD) 179,646 -3% -5.7 -89% 27,559 11,084 579 -15 -24,657 -29,109 164,913
Natures Sunshine Products (NATR) 178,574 74% 6.3 1% 216,251 91,513 368,198 272,204 3,103 21,118 132,233
Osmotica Pharmaceuticals (OSMT) 173,838 47% -2.2 -37% 643,835 385,925 246,700 116,977 -238,202 -172,965 378,458
Bioxcel Therapeutics (BTAI) 171,936 -5.2 -81% 34,278 9,121 0 0 -27,637 -27,500 141,971
LifeVantage (LFVN) 171,371 83% 12.0 13% 55,273 28,074 225,958 187,985 7,429 12,680 152,547
Aldeyra Therapeutics (ALDX) 166,240 -2.5 -68% 73,839 6,506 0 0 -50,397 -51,584 126,840
Acelrx Pharmaceuticals (ACRX) 165,720 -135% -2.6 -44% 115,112 133,531 2,196 -2,957 -51,102 -48,219 124,419
Adamas Pharmaceuticals (ADMS) 164,322 98% -2.3 -58% 200,231 157,528 23,928 23,393 -116,564 -98,464 225,113
Sesen Bio (SESN) 162,025 -1.2 -64% 127,612 112,243 0 0 -81,587 -81,373 97,074
Cue Biopharma (CUE) 159,852 0% -3.0 -108% 41,756 21,475 2,205 0 -44,969 -44,556 131,596
Ardelyx (ARDX) 157,002 99% -0.9 -75% 137,980 69,363 275 273 -103,599 -97,567 85,052
Tocagen (TOCA) 154,128 0% -2.1 -64% 85,234 48,748 18,036 0 -54,184 -51,880 107,907
Kezar Life Sciences (KZR) 153,252 -5.2 -26% 105,267 10,664 0 0 -27,805 -26,768 140,221
Galmed Pharmaceuticals (GLMD) 152,597 0% 90,600 2,706 0 0 0 0 128,438

Balance Sheet ($'000)2018-12-31
Cash42,565
Accounts Receivable
Inventory
PP&E327
Assets43,549
Accounts Payable1,604
Long-Term Debt
Liabilities4,660
Stockholders' Equity38,889
Income Statement ($'000)2018-12-31
Revenue
Cost of Revenue
Gross Profit
R&D14,558
SG&A5,404
Tax
Net Income-19,270
Cash Flow ($'000)2018-12-31
Cash Operating-13,509
Cash Investing-340
Cash Financing55,527